Dostarlimab or pembrolizumab plus chemotherapy in previously untreated metastatic non-squamous non-small cell lung cancer: the randomized PERLA phase II trial

PERLA is a global, double-blind, parallel phase II trial (NCT04581824) comparing efficacy and safety of anti-PD-1 antibodies dostarlimab and pembrolizumab, plus chemotherapy (DCT and PCT, respectively) as first-line treatment in patients with metastatic non-squamous NSCLC without known targetable genomic aberrations. Patients stratified by PD-L1 tumor proportion score and smoking status were randomized 1:1, receiving

• Lim, S. M.
• Peters, S.
• Ortega Granados, A. L.
• Pinto, G. D. J.
• Fuentes, C. S.
• Lo Russo, G.
• Schenker, M.
• Ahn, J. S.
• Reck, M.
• Szijgyarto, Z.
• Huseinovic, N.
• Zografos, E.
• Buss, E.
• Stjepanovic, N.
• O'Donnell, S.
• de Marinis, F.